BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

March 10 (Reuters) - Mineralys Therapeutics (MLYS.O), opens new tab said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and ...

RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...

Mineralys intends to use the net proceeds from the proposed offering to fund clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of hypertension. The therapy, called lorundrostat, hit the primary endpoint of ...

Mineralys Therapeutics is working on a treatment for patients with uncontrolled hypertension. Mineralys Therapeutics' stock price skyrocketed Monday morning after the Main Line biopharmaceutical ...

Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.29. The stock has a market cap of $712.65 million, a P/E ratio of -3.93 and a beta of 1.50.

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10 ...

(MENAFN- GlobeNewsWire - Nasdaq) RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical ...